Integrating novel therapies in the transplant paradigm

Cancer Journal

Volumn 15, Issue 6, 2009, Pages 479-484

  Harousseau, Jean Luc ^a  

^a Rene Gauducheau Cancer Center   (France)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Novel therapies

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 75149133966     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181c51ca3     Document Type: Review

References (57)

1. Harousseau J-L, Moreau P. Autologous stem-cell transplantation in multiple myeloma. N Engl J Med. 2009;360:2645-2654.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883.
4. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multpiple myeloma. A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183-196.
5. Kumar S, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma. Blood. 2008;111:2516-2520.
6. Harousseau J-L, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114:3139-3146.
7. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients treated with high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
8. Durie BG, Harousseau JL, San Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
9. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achieving at least very good partial remission is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term results if the IFM 99-02 and 99-04 trials. J Clin Oncol. In press.
10. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem autotransplants for newly diagnosed multiple myeloma. Blood. 1999;93: 55-65.
11. Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-12425
12. Cavo M, Tosi P, Zamagni E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.
13. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOVON 24 trial. Haematologica. 2007;92:928-935.
14. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489-3495.
15. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030. (Pubitemid 43357806)
16. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;15: 3289-3295.
17. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805-1810.
18. Spencer A, Prince HM, Roberts A, et al. Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure. J Clin Oncol. 2009;27:1788-1793.
19. Morgan GJ, Jackson GH, Davies FE, et al. Maintenance thalidomide may improve progression free but not overall survival:results from the myeloma IX maintenance randomisation. Blood. 2008;112:656.
20. Lokhorst HM, van der Holt B, Zweegman S, et al. Hovon-50. Final analysis of thalidomide combined with adriamycin,dexamethasone and high-dose melphalan. Clin Lymphoma Myeloma. In press.
21. Abdelkefi A, Ladeb S, Torjman L. Retractation of reference 17. Blood. 2009;113:6265.
22. Barlogie B, Pinedda-Roman M, van Rhee F, et al. Thalidomide arm of Total therapy 2 improves complete remission and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
23. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445-4451.
24. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometry is the most relevant prognostic factor relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017-4023.
25. Ladetto M, Pagliano G, Ferrero S, et al. Major shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-transplant consolidation with bortezomib, thalidomide and dexamethasone: a qualitative and quantitative PCR study (abstract). Blood. 2008; 112:3683.
26. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of Thalidomide plus Dexamethasone compared with Dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
27. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethsone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39.
28. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial (abstract). Blood. 2006;108:22a.
29. Harousseau J-L, Mathiot C, Attal M, et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: updated results of the IFM 2005-2101 trial. Presented at ASH/ASCO Symposium During ASH 2008. Atlanta, GA: ASH; 2008.
30. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (abstract). Blood. 2007;110:74.
31. Mazumder A, Kaufman J, Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008:22;1280-1281. (Pubitemid 351833803)
32. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008; 22:1282-1284.
33. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14: 795-798.
34. Lokhorst HM, Schidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124-127.
35. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study (abstract). Blood. 2007;110: 1051a.
36. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase II trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high-dose melphalan in patients with newly diagnosed multiple myeloma (abstract). Haematologica. 2009;94:473.
37. Cavo M, Tachetti, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade- thalidomide dexamethasone (VTD) compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma (abstract). Blood. 2008; 112:158.
38. Rosinol L, Cibeira MT, Martinez J, et al. Thalidomide/dexamethasone vs bortezomib/thalidomide/dexamethasone vs VBMCP/VBAP/velcade as induction regimens prior to autologous stem cell transplantation in younger patients with multiple myeloma: first results of a prospective phase III PETHEMA/ GEM trial (abstract). Blood. 2008;112:654.
39. Barlogie B, Anaissie E, Van Rhee F, et al. Incorporating Bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-185.
40. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remission in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140:625-634.
41. Facon T, Mary JY, Hulin C, et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;307:1209-1218.
42. Palumbo A, Bringhen S, Liberati A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood. 2008;112:3107-3114.
43. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;35:906-917.
44. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, lenalidomide treatment for newly diagnosed myeloma:a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459-4465.
45. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin/Revlimid/ Dexamethasone) combination therapy results in high complete and ovaerall response rates in treatment-naïve symptomatic multiple myeloma. Blood. 2008;111:1101-1109.
46. Richardson PG, Lonial S, Jakubowiak S, et al. Safety and efficacy of lenalidomide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:459s.
47. Harousseau J-L. The allogeneic dilemma. Bone Marrow Transplant. 2207; 40:1123-1128.
48. Crawley C, Lalancette M, Szydlo R, et al. Outcomes of reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;105:4532-4539. (Pubitemid 40720805)
49. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588-3594.
50. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopietic cell transplantation and nonmyeloablative allografting. Blood. 2009;113:3383-3391.
51. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
52. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of IFM 99-03 and IFM 99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood. 2008;112:3914-3915.
53. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective Pethema study of tandem autologous transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in multiple myeloma. Blood. 2008;112:3591-3592.
54. Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica. 2006;91:837-839.
55. Tosi P, Zamagni E, Cangini B, et al. Complete remission upon bortezomibdexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. Ann Hematol. 2006;85: 549-558.
56. Van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107:3415-3416.
57. Kroger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocute infusions and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37:791-798.